European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines

JA Witjes, HM Bruins, R Cathomas, EM Compérat… - European urology, 2021 - Elsevier
Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline

SS Chang, SA Boorjian, R Chou, PE Clark… - The Journal of …, 2016 - auajournals.org
Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

T Powles, J Bellmunt, E Comperat… - Annals of …, 2022 - annalsofoncology.org
Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …

Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma

DF Bajorin, JA Witjes, JE Gschwend… - … England Journal of …, 2021 - Mass Medical Soc
Background The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma
after radical surgery is not clear. Methods In a phase 3, multicenter, double-blind …

Standard or extended lymphadenectomy for muscle-invasive bladder cancer

SP Lerner, C Tangen, RS Svatek… - … England Journal of …, 2024 - Mass Medical Soc
Background Whether extended lymphadenectomy is associated with improved disease-free
and overall survival, as compared with standard lymphadenectomy, among patients with …

Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder

B Szabados, M Kockx, ZJ Assaf, PJ van Dam… - European Urology, 2022 - Elsevier
Background Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer
(MIBC). Objective To report on 2-yr disease-free (DFS) and overall (OS) survival including …

Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for …

C Pfister, G Gravis, A Fléchon, M Soulié, L Guy… - European Urology, 2021 - Elsevier
Background Perioperative chemotherapy (neoadjuvant or adjuvant) has been developed to
increase overall survival for nonmetastatic muscle-invasive bladder cancer (MIBC) …

Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer

JA Witjes, T Lebret, EM Compérat, NC Cowan… - European urology, 2017 - Elsevier
Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …

Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients

RE Hautmann, RC de Petriconi, C Pfeiffer, BG Volkmer - European urology, 2012 - Elsevier
BACKGROUND: The optimal treatment strategy for muscle-invasive bladder cancer (BCa)
remains controversial. OBJECTIVE: Better define the long-term outcomes of radical …

Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature

LA Kluth, PC Black, BH Bochner, J Catto, SP Lerner… - European urology, 2015 - Elsevier
Context This review focuses on risk assessment and prediction tools for bladder cancer
(BCa). Objective To review the current knowledge on risk assessment and prediction tools to …